Cencora, Inc. $COR Shares Purchased by Park National Corp OH

Park National Corp OH boosted its stake in Cencora, Inc. (NYSE:COR) by 9.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,749 shares of the company’s stock after buying an additional 2,887 shares during the quarter. Park National Corp OH’s holdings in Cencora were worth $10,288,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. United Bank lifted its position in shares of Cencora by 4.5% in the second quarter. United Bank now owns 7,032 shares of the company’s stock valued at $2,109,000 after acquiring an additional 305 shares in the last quarter. Nebula Research & Development LLC purchased a new stake in shares of Cencora during the second quarter worth approximately $595,000. Treasurer of the State of North Carolina increased its position in shares of Cencora by 7.9% during the second quarter. Treasurer of the State of North Carolina now owns 85,534 shares of the company’s stock worth $25,647,000 after purchasing an additional 6,244 shares in the last quarter. Diversify Advisory Services LLC increased its position in shares of Cencora by 94.1% during the second quarter. Diversify Advisory Services LLC now owns 2,585 shares of the company’s stock worth $747,000 after purchasing an additional 1,253 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in Cencora by 26.0% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 73,452 shares of the company’s stock valued at $22,025,000 after purchasing an additional 15,154 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Price Performance

Shares of COR stock opened at $271.99 on Friday. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The company has a market capitalization of $52.92 billion, a PE ratio of 20.86, a price-to-earnings-growth ratio of 1.47 and a beta of 0.59. The firm’s 50-day moving average is $284.59 and its two-hundred day moving average is $324.35. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). The firm had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period last year, the company earned $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Analysts predict that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora announced that its board has initiated a stock repurchase program on Thursday, May 21st that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to buy up to 3.9% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were issued a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. Cencora’s dividend payout ratio is currently 18.40%.

Analyst Ratings Changes

A number of research analysts have weighed in on COR shares. Wells Fargo & Company decreased their price objective on Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a report on Monday, May 11th. Robert W. Baird dropped their target price on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Morgan Stanley set a $342.00 target price on shares of Cencora in a research report on Friday, May 8th. Barclays decreased their price target on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 10th. Finally, Leerink Partners restated an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Twelve analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $374.00.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.